Mega Genomics Limited stock analysis
Want to see HK:6667 full AI Analyst Report?
Mega Genomics Limited (6667) Stock Price & Analysis
6667 Stock Chart & Stats
- Day’s Range
- HKD 6.46 - HKD 6.69
- 52-Week Range
- HKD 4.80 - HKD 7.53
- Previous Close
- HKD 6.79
- Volume
- N/A
- Average Volume (3M)
- 84.74K
- Market Cap
- HKD 1.52B
- Enterprise Value
- HKD 995.76M
- Total Cash (Recent Filing)
- HKD 424.49M
- Total Debt (Recent Filing)
- HKD 28.52M
- Price to Earnings (P/E)
- 46.2
- Beta
- -0.18
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- May 26, 2026
- Dividend Yield
- 2.63%
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Very low leverage and a substantial equity base provide financial resilience and flexibility. This structure can help the company withstand operating volatility, fund initiatives without excessive borrowing, and preserve strategic options over the next several quarters.
Strong Recent Revenue Growth
Rapid recent revenue expansion indicates improving commercial scale and demand relative to the prior year. If maintained, a larger revenue base can support operating leverage, broaden market reach, and provide more resources for continued business development.
Historical Cash-generation Capability
Although the latest year was weak, prior substantial operating cash generation shows the business has produced cash under more favorable conditions. That historical capability provides a foundation for recovery if cash conversion stabilizes and supports internally funded growth.
Bears Say
Negative Latest-year Cash Flow
Negative operating and free cash flow despite accounting profit signals weak recent cash conversion. Persistent outflows could reduce internally available funding, increase reliance on the strong balance sheet, and constrain investment or shareholder-return capacity.
Margin And Earnings Compression
Material margin contraction means additional revenue is currently producing less profit than in earlier peak years. The decline in net income despite higher sales raises concerns about earnings quality and limits the durability of reported top-line growth.
Low Returns And Earnings Cyclicality
Modest returns on a large equity base indicate that capital is not currently generating strong profitability. Combined with the prior annual loss, this points to earnings cyclicality that may make results less predictable and weaken compounding potential.
Mega Genomics Limited News
6667 FAQ
What was Mega Genomics Limited’s price range in the past 12 months?
What is Mega Genomics Limited’s market cap?
When is Mega Genomics Limited’s upcoming earnings report date?
How were Mega Genomics Limited’s earnings last quarter?
Is Mega Genomics Limited overvalued?
Does Mega Genomics Limited pay dividends?
What is Mega Genomics Limited’s EPS estimate?
How many shares outstanding does Mega Genomics Limited have?
What happened to Mega Genomics Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Mega Genomics Limited?
What is the TipRanks Smart Score and how is it calculated?
Mega Genomics Limited Stock Smart Score
Company Description
Mega Genomics Limited
Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service that assesses the genetic risk of developing myocardial infarction and heart failure; cardiovascular and cerebrovascular disease risk assessment packages; hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; cervical cancer genetic methylation testing, a cervical cancer test; telomere length genetic testing that assesses the cell age and aging rate of a person; and personal whole genome test plus, a service that assesses the risk of developing multiple types of diseases and provides interpretation for various individual traits and medication advice. It also offers whole exome sequencing package for adults, a service that assesses the risk of developing multiple high-risk diseases, hereditary cancers, recessive genetic diseases, and types of complex diseases, as well as multiple drugs, dietary nutrition items, and exercise and fitness items; folate metabolic capacity assessment testing kits to assess the risk of developing cardiovascular and cerebrovascular diseases; ApoE gene testing for testing Alzheimer’s disease; BRCA1/2 gene mutation testing kits; Alzheimer’s disease screening kits; colorectal cancer screening kits; gastric cancer screening kits; lung nodule auxiliary diagnostic kits; and cervical cancer screening kits to health checkup centers and hospitals. The company was founded in 2016 and is headquartered in Beijing, China.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Jing Jiang
- Employees
- 196
- Website
- www.megagenomics.cn
- Address
- 401 Health Work, Beijing, BE, 100080, CN
Mega Genomics Limited (6667) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 14 |
| Technical Analysis | 4 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |









